The potential functional conjugation between CD47 and HER2 was indicated by the striking difference in CD47-expression levels in HER2+ versus HER2− BC cells (Fig. 1b), and HER2+ versus HER2− tumors from BC patients (Fig. 1c, d). This evidence concerns the gene ERBB2 and breast cancer.